Tuesday Jul 15 | Triangle Business Journal
Virtual biotech: Real money, real questions
Can you build a drug company without bricks and mortar? For a local startup biotech firm, that's not a hypothetical question.
POZEN To Present at Baird's 2008 Growth Stock Conference
May 1, 2008 - POZEN Inc. announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at Baird's 2008 Growth Stock Conference on Tuesday, May 13, ... via Med Ad News
The companies announced Friday that the FDA had set the finish line for submitting a marketing application for the companies' cholesterol-lowering drug, mipomersen, a little further down the road than the ... via Motley Fool
Thursday's pre-market gainers and losers
Here are the biggest percentage gainers and losers in pre-market trading among companies with a market cap between $50 million and $750 million: Biggest percentage gainers: Encore Wire Corp . via All Stories
Bull and bear of the week named
Bull and Bear of the Week from Zacks.com Charles Rotblut, senior market analyst for Zacks.com, made Pozen his pick for "Bull of the Week," noting that the company just received FDA approval for its migraine ... via MarketWatch
Treximet (sumatriptan And Naproxen Sodium) Tablets Approved By FDA For Acute Treatment Of Migraine
“The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients.”
Main Category: Headache / Migraine Also Included In: Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 21 Apr 2008 - 0:00 PDT printer ... via Medical News Today
Treximet Approved for Migraines
The U.S. Food and Drug Administration has approved Pozen Inc.'s Treximet to treat migraines, the agency said Friday on its Web site. via HON
Wednesday's small-cap gainers and losers
Here are the day's biggest percentage gainers and losers, along with top volume leaders, among companies with a market cap between $100 million and $750 million: Biggest percentage gainers: EnerNOC Inc. via All Stories
Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by...
“The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients.”
Clinical studies show Treximet provided significantly more patients migraine pain relief compared to sumatriptan 85 mg LONDON, April 15 /PRNewswire-FirstCall/ -- GlaxoSmithKline and POZEN Inc. via Earth Times
Option Update: POZEN option prices Elevated into PDUFA
Posted Apr 14th 2008 10:10AM by Paul Foster Filed under: Options Pozen closed at $10. POZN's Treximet PDUFA is April 15, 2008. via Blogging Stocks
Pozen Shares Sink on Concern That FDA Warning to GlaxoSmithKline Could Delay Migraine Drug
Shares of Pozen Inc. fell Tuesday on speculation that a federal warning letter issued to GlaxoSmithKline PLC could delay approval of a drug the companies are developing. via Canadian Business Magazine
Posted Tue Feb 26, 04:53 pm ET Posted By: Jason Napodano, CFA Pozen, Inc. announced on February 25, 2008 the company has submitted the findings from a short-term genotoxic study as part of the complete response ... via Zacks Analyst Blog
POZEN Reports Fourth Quarter and Year End 2007 Results
POZEN Inc. , today announced results for the fourth quarter and year ended December 31, 2007. via Earth Times
Pozen posts profit for year, loss for quarter
“Everybody is holding their breath for a Treximet approval”
Pozen's fourth-quarter loss of $4.2 million beat analysts' expectations, and the Chapel Hill company reported its second annual profit in three years Tuesday. via News Observer
A gauge of consumer confidence in February is expected to dip from the January level, while a measure of inflation is expected to increase. via News Observer
POZEN's Dr. William Kelce Appointed Adjunct Associate Professor at UNC, Chapel Hill
Feb 21, 2008 - POZEN Inc. , today announced that Dr. William R. Kelce, vice president, preclinical and early clinical development, has been appointed adjunct associate professor, Department of Pediatrics, ... via Med Ad News
Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck 's Zocor, which isn't patent-protected anymore. via Fool.com
POZEN to Present at the Susquehanna Financial Group's Second Annual...
Feb 14, 2008 - POZEN Inc. announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at Susquehanna Financial Group's Second Annual SIGnificant ... via Med Ad News
Businessnetwire.us: Arthritis Sufferers Take Note: Stock News You Can Use
“Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.”
RDATE:12022008 New York, NY -- HealthSonix, Inc. ; Exactech, Inc. ; POZEN Inc. ; Protalex, Inc. via TMCnet
Public relations, press release distribution, investor relations, SEC filing
FSV Payment Systems Inc., a leading provider of stored value processing and prepaid card solutions, and MiCash Inc., an innovative licensed money transfer business, - 01/17/2008 - 06:00 AM BOSTON-- --Converted ... via Business Wire
Read more articles in the Pozen News Archives.
For up to the minute news, check out the Pozen News Wire.
Want to add Pozen News headlines to your web site? Get the widget here.
I edit this news page on Topix when no humans are available to help.
People just like you make Pozen News on Topix better every day. If you're interested in becoming an editor, apply today!
Recent Forum Discussions
News TrendsThe hottest topics in the news right now
Most Popular
Comment?
Topix Quick Poll
